While most pharma companies are busy crying about pricing pressure and regulatory headaches, Strides Pharma decided to pull a Bollywood-style comeback – with high drama, a few surprises, and an ending where they still look good. The management flexed their numbers like a gym bro in front of a mirror, leaving investors both impressed and suspicious.
Here’s what we decoded from the hour-long corporate therapy session they call a concall.
At a Glance
- Revenue hit ₹1,120 Cr – CFO swears this isn’t a typo or accounting sorcery.
- EBITDA margin at 19.5% – the kind of margin that makes competitors cry in the shower.
- PAT jumps 81% YoY – operational, not some one-off magic.
- Net debt down to ₹1,496 Cr – still a mountain, but at least they’re climbing.
- Stock? Traders are having a love-hate relationship – one day they cheer, next day they panic.
The Story So Far
Last quarter, Strides promised growth, profitability, and a toned balance sheet. This quarter? They actually delivered. Revenue climbed, margins expanded, and debt shrank – which is more than many pharma peers can say.
Their U.S. business kept the cash registers ringing despite tariff scares. Growth markets went full turbo with a 32% jump, while the access markets sulked because donor funding is still on vacation. Controlled substances and nasal sprays are the new toys they’re betting on – sounds fancy, but the real test will be execution.
In short, Strides showed up, worked out, and flexed. Investors are watching if they’ll keep the gains or relapse into old habits.
Management’s Key Commentary
- On Growth:
“We are optimistic.”
Translation: Pray the U.S. tariffs don’t ruin the party.
- On Costs:
“Inflation is under control.”
Sure, just like everyone’s diet after New Year.
- On U.S. Business:
“Targeting $400M revenue by FY28.”
Because nothing says confidence like throwing a big round number.
- On Beyond Generics:
“Nasal sprays, patches, and controlled substances will drive growth.”
Investors: Sounds high… on margins.
- On Debt:
“Net debt is comfortable.”
Comfortable for them, maybe not for investors staring at ₹1,496
